ASCOT-LLA

Jump to: navigation, search

Low Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low LDL
High LDL

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Prognosis and Complications

Diagnosis

Laboratory Findings

Treatment

Medical Therapy

Landmark Trials

Future or Investigational Therapies

Case Studies

Case #1

ASCOT-LLA On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of ASCOT-LLA

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on ASCOT-LLA

CDC on ASCOT-LLA

ASCOT-LLA in the news

Blogs on ASCOT-LLA

Directions to Hospitals Treating Low density lipoprotein

Risk calculators and risk factors for ASCOT-LLA

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Click here to download slides for ASCOT-LLA.

Overview

Hypertensive patients (n=10305) with total cholesterol < 251 mg/dL were randomly assigned to atorvastatin 10 mg daily and a significant reduction in non-fatal MI, fatal CHD and stoke (fatal and non-fatal) was noticed. No significant difference was observed on all-cause mortality. The trial was stopped earlier than expected of 5 years because of beneficial treatment[1].

References


Linked-in.jpg